Prevalence and Clinical Outcome of FMS-like Tyrosine Kinase Mutations Amongst Patients with Core Binding Factor – Acute Myeloid Leukemia: Systematic Review and Meta-analysis
Two classes of mutation, namely, type-I and type-II mutations, work synergistically to develop acute myeloid leukemia (AML) in vivo. Type-I mutations occur in the genes (FLT3, WT1, KIT, RAS, etc) involved in signal transduction pathways which contribute to the growth and survival, whereas type-II mutations (RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, NPM1 and CEBPA) act by blocking differentiation and/or enhancing self-renewal of leukemic cells.1
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Shyam Srinivasan, Shathish Kumar, Kalasekhar Vijayasekharan, Amit Kumar Agrawal Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Genetics | Hematology | Leukemia | Lymphoma | Myeloma